Asset Details
Do you wish to reserve the book?
Two Phase 3 Trials of Baricitinib for Alopecia Areata
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Two Phase 3 Trials of Baricitinib for Alopecia Areata
Do you wish to request the book?
Two Phase 3 Trials of Baricitinib for Alopecia Areata
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Two Phase 3 Trials of Baricitinib for Alopecia Areata
2022
Overview
Alopecia areata is a distressing disorder of hair loss that is mediated partly by cytokines dependent on Janus kinases. The JAK1 and JAK2 inhibitor baricitinib reduced the extent of hair loss in two randomized trials over a period of 36 weeks.
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Allergy
/ Alopecia
/ Alopecia Areata - drug therapy
/ Azetidines - adverse effects
/ Azetidines - therapeutic use
/ Baldness
/ Creatine
/ Hair
/ Humans
/ Janus Kinase Inhibitors - adverse effects
/ Janus Kinase Inhibitors - therapeutic use
/ Oncology
/ Placebos
/ Scalp
/ Sulfonamides - adverse effects
/ Sulfonamides - therapeutic use
/ T-Cells
